Cite

HARVARD Citation

    Gettinger, S. et al. (n.d.). 3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses. European journal of cancer. pp. S632-. [Online]. 
  
Back to record